- Home
- NEN vs TARA Comparison
NEN vs TARA Comparison
Compare NEN & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
NEN
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
Current Price
Company Overview
Basic Information| Metric | NEN | TARA |
|---|---|---|
| Founded | 1977 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.0M | 236.1M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NEN | TARA |
|---|---|---|
| Price | $54.45 | $3.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | 1.2K | ★ 347.5K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,196,544.00 | $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.68 | ★ N/A |
| Revenue Growth | ★ 10.76 | N/A |
| 52 Week Low | $52.08 | $3.02 |
| 52 Week High | $73.50 | $7.82 |
Technical Indicators
Market Signals| Indicator | NEN | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 49.12 |
| Support Level | $52.08 | $3.73 |
| Resistance Level | $66.30 | $4.17 |
| Average True Range (ATR) | 1.14 | 0.14 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 39.18 | 57.50 |
Price Performance
Historical ComparisonAbout NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.